Material Modifications to Rights of Security Holders

Analyst Summary

CNS Pharmaceuticals implemented a 1-for-50 reverse stock split effective February 21, 2025.
The reverse stock split aims to increase the company’s per share trading price and meet Nasdaq’s minimum share price requirement.
Post-split, the common stock will trade under the same symbol (CNSP) but with a new CUSIP number (18978H409).
The number of outstanding shares was reduced from approximately 136.93 million to approximately 2.74 million.
Authorized shares of common stock will remain at 300 million shares.
Proportionate adjustments were made to outstanding stock options, restricted stock unit awards, and warrants.

The reverse stock split is primarily intended to increase the Company’s per share trading price.
Compliance with Nasdaq’s listing requirement regarding minimum share price.